STOCK TITAN
  1. Home
  2. Sec-filings
  3. AVTX
  4. [Form 4] Avalo Therapeutics, Inc. Insider Trading Activity

AVTX director exercises options and reports insider stock sales

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. (AVTX) reported insider activity by one of its directors involving common stock and stock options on November 14, 2025. The director exercised a stock option to acquire 8,200 shares of common stock at an exercise price of $9.88 per share and then sold those 8,200 shares at a weighted average price of $14.3474 per share. On the same date, the director also sold an additional 3,167 shares of common stock at $14.30 per share, for total reported sales of 11,367 shares. Following these transactions, the director reported owning 0 shares of common stock directly and 16,400 stock options with an exercise price of $9.88 per share, expiring on August 13, 2034, which vest in three equal annual installments on March 28, 2025, 2026 and 2027.

Positive

  • None.

Negative

  • None.
Insider Goldman Jonathan
Role Director
Sold 11,367 shs ($163K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 8,200 $0.00 --
Sale Common Stock 3,167 $14.30 $45K
Exercise Common Stock 8,200 $9.88 $81K
Sale Common Stock 8,200 $14.3474 $118K
Holdings After Transaction: Stock Option (Right to Buy) — 16,400 shares (Direct); Common Stock — 0 shares (Direct)
Footnotes (1)
  1. The reported securities were sold in multiple transactions at prices ranging from $14.02 to $14.60. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The stock option vests 1/3 on March 28, 2025, March 28, 2026 and March 28, 2027, subject to the Eligible Director's continued service on such vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Goldman Jonathan
(Last) (First) (Middle)
C/O AVALO THERAPEUTICS, INC.
1500 LIBERTY RIDGE DRIVE, SUITE 321
(Street)
WAYNE PA 19087
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/14/2025 S 3,167 D $14.3 0 D
Common Stock 11/14/2025 M 8,200 A $9.88 8,200 D
Common Stock 11/14/2025 S 8,200 D $14.3474(1) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $9.88 11/14/2025 M 8,200 (2) 08/13/2034 Common Stock 8,200 $0 16,400 D
Explanation of Responses:
1. The reported securities were sold in multiple transactions at prices ranging from $14.02 to $14.60. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
2. The stock option vests 1/3 on March 28, 2025, March 28, 2026 and March 28, 2027, subject to the Eligible Director's continued service on such vesting date.
/s/ Donald R. Reynolds, by Power of Attorney 11/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Avalo Therapeutics (AVTX) report on this Form 4?

Avalo Therapeutics (AVTX) disclosed that a director exercised a stock option for 8,200 shares at $9.88 per share and sold a total of 11,367 shares of common stock on November 14, 2025.

How many Avalo Therapeutics (AVTX) shares did the director sell and at what prices?

The director sold 3,167 shares of common stock at $14.30 per share and 8,200 shares at a weighted average price of $14.3474 per share, for total reported sales of 11,367 shares.

What stock options does the Avalo Therapeutics (AVTX) director still hold after the transactions?

After the reported trades, the director holds 16,400 stock options with an exercise price of $9.88 per share, expiring on August 13, 2034.

What is the vesting schedule of the Avalo Therapeutics (AVTX) director stock options mentioned?

The stock option referenced vests in three equal installments of one-third each on March 28, 2025, March 28, 2026 and March 28, 2027, subject to the director’s continued service.

Does the Avalo Therapeutics (AVTX) director still own common stock after these Form 4 transactions?

Following the reported sales on November 14, 2025, the director reported owning 0 shares of common stock directly and holding only stock options.

What role does the reporting person have at Avalo Therapeutics (AVTX)?

The reporting person is identified as a director of Avalo Therapeutics, Inc. and filed the Form 4 as a single reporting person.